AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure
Launched by TECHNICAL UNIVERSITY OF MUNICH · Oct 18, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The AlEX-DHF clinical trial is studying how a combination of exercise and a procedure called ablation can help people with heart failure with preserved ejection fraction (HFpEF) and short-persistent atrial fibrillation (Afib). Researchers believe that this combination can improve how well the heart and body use oxygen during exercise, making everyday activities easier for patients. The exercise part of the study includes a 12-week program with video-based training that focuses on endurance, strength, and breathing exercises.
To participate in this trial, individuals should be diagnosed with HFpEF and have experienced symptoms of short-persistent Afib within the last year. Unfortunately, those with certain heart conditions, previous ablation therapy, or other serious health issues will not be eligible. Participants can expect to be part of a supportive exercise program while also receiving the ablation procedure, which aims to help manage their heart condition better. This trial is currently recruiting participants aged between 65 and 74, and aims to improve the quality of life for those affected by these heart issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed heart failure with preserved ejection fraction
- • Symptomatic short-persistent atrial fibrillation (diagnosis within 1 year of study inclusion)
- Exclusion Criteria:
- • Paroxysmal, long-persistent or permanent atrial fibrillation
- • Clinically unstable coronary artery disease or acute coronary syndrome
- • Physical and/or mental inability to perform exercise testing
- • Prior ablation therapy
- • Precapillary pulmonary hypertension at rest
- • Intracardiac shunts
- • Left ventricular ejection fraction \<50%
- • High-degree valve insufficiency or stenosis (greater than grade 1 at rest)
About Technical University Of Munich
The Technical University of Munich (TUM) is a leading research institution in Germany, renowned for its commitment to excellence in education, innovation, and technology transfer. With a strong emphasis on interdisciplinary collaboration, TUM fosters advancements in various fields, including medicine and life sciences. The university actively engages in clinical research, aiming to translate scientific discoveries into practical applications that improve patient outcomes. Through its state-of-the-art facilities and a network of partnerships with hospitals and industry, TUM is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards and contribute significantly to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Trial Officials
Simon Wernhart, MD
Principal Investigator
Technical University of Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported